XZB-0004
- Generic Name
- XZB-0004
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Phase 1
Recruiting
- Conditions
- Lung Cancer, Nonsmall CellLung Cancer Stage IVLung Cancer Metastatic
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- SignalChem Lifesciences Corporation
- Target Recruit Count
- 92
- Registration Number
- NCT05860296
- Locations
- 🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇺🇸Horizon Verdi Oncology, Lafayette, Indiana, United States
A Study of XZB-0004 in Patients With Solid Tumors
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05772455
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT05740917
- Locations
- 🇨🇳
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- SignalChem Lifesciences Corporation
- Target Recruit Count
- 22
- Registration Number
- NCT05278845
- Locations
- 🇨🇦
Syneos Health Clinique Inc. (Quebec), Quebec, Canada
Safety Study of SLC-391 in Subjects With Solid Tumors
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- SignalChem Lifesciences Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT03990454
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath